公开(公告)号：EP4219477A1

公开(公告)日：2023-08-02

申请号：EP23155266.2

申请日：2014-07-16

申请人： Otsuka Pharmaceutical Co., Ltd.

发明人： Sato, Seiji ,  Matsuda, Satoshi ,  Matsumura, Chiharu ,  Itotani, Motohiro ,  Shinohara, Toshio ,  Fujita, Shigekazu ,  Sakurai, Yohji ,  Tai, Kuninori ,  Fukushima, Tae ,  Kanemoto, Naohide ,  Okamoto, Takashi

IPC分类号： C07D403/12 ,  C07D401/14 ,  C07D405/14 ,  C07D413/14 ,  C07D401/12 ,  C07D403/14 ,  C07D405/12 ,  C07D411/12 ,  C07D411/14 ,  C07D413/12 ,  C07D417/12 ,  C07D417/14 ,  C07D249/04 ,  C07D249/06 ,  A61K31/4192 ,  A61P3/00 ,  A61P9/00

摘要： This invention relates to a cyanotriazole compound represented by the formula (1):

wherein each symbols are defined in the specification,
or a salt thereof. The compound or a salt thereof stimulates the citric acid cycle activity and/or improves hyperglycemia with less side effects, and excellent safety, and therefore, it is useful for treating and/or preventing diseases or disorders on which citric acid cycle activation and/or improvement of hyperglycemia has a prophylactic and/or therapeutic effect, for example, diabetes, impaired glucose tolerance, insulin resistance, diabetic complications, obesity, dyslipidemia, hepatic steatosis, atherosclerosis and/or cardiovascular disease, as well as diseases or disorders that would benefit from stimulating energy expenditure.